Overview
- The 10,000-square-foot facility is purpose-built to produce Novartis’s FDA-approved radioligand therapies with capacity for future expansion.
- The new site is intended to boost manufacturing capacity and strengthen the domestic supply chain for time-sensitive, custom RLT doses.
- Novartis says local production will help maintain a greater than 99.9% on-time delivery rate for patients across the western U.S., Alaska and Hawaii.
- The company has filed the Carlsbad plant with the FDA as an additional U.S. point of supply, with commercial manufacturing to begin once approved.
- Beyond Carlsbad, Novartis plans new RLT plants in Florida and Texas, expansions in Durham, Indianapolis and Millburn, and a San Diego R&D hub, as it projects nearly $50 billion in U.S. investment over five years.